Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-Label Study of Iparomlimab and Tuvonralimab to Facilitate Surgery Avoidance in Women With Resectable, Mismatch Repair-Deficient Endometrial Cancer

NCT07369986 is registered in ClinicalTrials.gov with Women's Hospital School Of Medicine Zhejiang University as lead sponsor.

NCT NCT07369986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07369986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-Label Study of Iparomlimab and Tuvonralimab to Facilitate Surgery Avoidance in Women With Resectable, Mismatch Repair-Deficient Endometrial Cancer
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, immunotherapy, mismatch repair deficiency